

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0104 |
| Estimated average burden hours per response: | 0.5 |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | |
|---|--|---|---|
| 1. Name and Address of Reporting Person* <u>VERTEX PHARMACEUTICALS INC / MA</u> (Last) (First) (Middle) <u>130 WAVERLY STREET</u> (Street) <u>CAMBRIDGE MA 02139</u> (City) (State) (Zip) | 2. Date of Event Requiring Statement (Month/Day/Year) <u>01/25/2006</u> | 3. Issuer Name and Ticker or Trading Symbol <u>Altus Pharmaceuticals Inc. [ALTU]</u> | |
| | | 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below) | 5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person |

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|
| Redeemable Preferred Stock | 450,000 | D | |
| Common Stock | 466,680 ⁽¹⁾⁽²⁾ | D | |

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|---------------------------|---|----------------------------|--|--|---|
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | |
| Warrants | 09/26/2001 | 02/01/2009 | Common Stock | 1,962,494 ⁽¹⁾ | 5.64 | D | |
| Series A Preferred Stock | 09/26/2001 | 01/31/2006 ⁽³⁾ | Common Stock | 381,596 ⁽¹⁾ | 5.73 | D | |

Explanation of Responses:

- After taking into account a 1:2.293 reverse stock split of the Issuer's Common Stock and, in the case of Warrants and the Series A Preferred Stock, adjustments to the applicable exercise price or conversion price, respectively, as a result of such reverse stock split.
- Includes 30,528 (post-split) shares held by Joshua S. Boger, the President and Chief Executive Officer of Vertex Pharmaceuticals Incorporated, for which Vertex disclaims beneficial ownership.
- Reflecting the anticipated date of the closing of the Issuer's initial public offering of common stock, upon which the Series A Preferred Stock will convert into the indicated number of shares of Common Stock.

Remarks:

Kenneth S. Boger, Attorney-In-Fact 01/25/2006

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.